CN101410108B - 用于治疗特定耐药性肿瘤的激酶抑制剂的应用 - Google Patents

用于治疗特定耐药性肿瘤的激酶抑制剂的应用 Download PDF

Info

Publication number
CN101410108B
CN101410108B CN2007800105497A CN200780010549A CN101410108B CN 101410108 B CN101410108 B CN 101410108B CN 2007800105497 A CN2007800105497 A CN 2007800105497A CN 200780010549 A CN200780010549 A CN 200780010549A CN 101410108 B CN101410108 B CN 101410108B
Authority
CN
China
Prior art keywords
abl
pyrazole
nafoxidine
benzoylamide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800105497A
Other languages
English (en)
Chinese (zh)
Other versions
CN101410108A (zh
Inventor
D·凡切利
A·伊萨奇
M·莫多格诺
J·摩尔
L·拉斯科尼
C·索悉尼
R·鲁比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of CN101410108A publication Critical patent/CN101410108A/zh
Application granted granted Critical
Publication of CN101410108B publication Critical patent/CN101410108B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2007800105497A 2006-03-30 2007-03-29 用于治疗特定耐药性肿瘤的激酶抑制剂的应用 Expired - Fee Related CN101410108B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06112023 2006-03-30
EP06112023.4 2006-03-30
PCT/EP2007/053041 WO2007113212A2 (en) 2006-03-30 2007-03-29 Use of a kinase inhibitor for the treatment of particular resistant tumors

Publications (2)

Publication Number Publication Date
CN101410108A CN101410108A (zh) 2009-04-15
CN101410108B true CN101410108B (zh) 2012-08-15

Family

ID=38191079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800105497A Expired - Fee Related CN101410108B (zh) 2006-03-30 2007-03-29 用于治疗特定耐药性肿瘤的激酶抑制剂的应用

Country Status (13)

Country Link
US (1) US8084455B2 (de)
EP (1) EP2004180A2 (de)
JP (1) JP5274444B2 (de)
CN (1) CN101410108B (de)
AR (1) AR060149A1 (de)
AU (1) AU2007233784A1 (de)
BR (1) BRPI0710179A2 (de)
CA (1) CA2647186A1 (de)
CL (1) CL2007000904A1 (de)
EA (1) EA200870305A1 (de)
MX (1) MX2008012019A (de)
TW (1) TW200808311A (de)
WO (1) WO2007113212A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5547487B2 (ja) * 2006-11-03 2014-07-16 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗癌化合物の投与方法
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JP5851990B2 (ja) * 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
GB2508652A (en) * 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
CN103113355B (zh) * 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
EP3076963A4 (de) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Kombination aus aurorakinaseinhibitoren und anti-cd30-antikörpern
CN105037399B (zh) * 2014-04-17 2017-04-26 深圳永泽医药股份有限公司 一类Bcr‑Abl双倍体抑制剂及制备方法与用途
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kiranmai Gumireddy, et al..A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.《PNAS》.2005,第102卷(第6期),1992-1997. *
Todd A. Carter, et al..Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.《PNAS》.2005,第102卷(第31期),11011-11016. *
ToddA.Carter et al..Inhibition of drug-resistant mutants of ABL

Also Published As

Publication number Publication date
CA2647186A1 (en) 2007-10-11
US20100035876A1 (en) 2010-02-11
CN101410108A (zh) 2009-04-15
WO2007113212A2 (en) 2007-10-11
WO2007113212A3 (en) 2008-01-24
AU2007233784A1 (en) 2007-10-11
TW200808311A (en) 2008-02-16
US8084455B2 (en) 2011-12-27
CL2007000904A1 (es) 2008-02-22
AR060149A1 (es) 2008-05-28
JP5274444B2 (ja) 2013-08-28
EA200870305A1 (ru) 2009-02-27
EP2004180A2 (de) 2008-12-24
BRPI0710179A2 (pt) 2011-08-09
JP2009531386A (ja) 2009-09-03
MX2008012019A (es) 2008-10-03

Similar Documents

Publication Publication Date Title
CN101410108B (zh) 用于治疗特定耐药性肿瘤的激酶抑制剂的应用
Kitagawa et al. Activity‐based kinase profiling of approved tyrosine kinase inhibitors
Koch et al. Inhibitors of c-Jun N-terminal kinases: an update
Goldenberg-Furmanov et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts
Okaniwa et al. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1, 3-benzothiazole derivatives
US20050234094A1 (en) Inhibition of protein kinases with piridinylimidazoles
JP2015523397A (ja) Ｃｄｋ４／６阻害剤およびｂ−ｒａｆ阻害剤の組合せ医薬
KR20180033194A (ko) 키랄 디아릴 매크로사이클 및 이것의 용도
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
CN116568671A (zh) 杂环Cullin-RING泛素连接酶化合物及其用途
Gustafson et al. Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia
KR101153647B1 (ko) Ｋｉｔ 돌연변이형에 대한 저해제
Qin et al. Development of organometallic S6K1 inhibitors
Kusuma et al. Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)
CN107296807A (zh) Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用
Ocasio et al. Type II kinase inhibitors targeting Cys-gatekeeper kinases display orthogonality with wild type and Ala/Gly-gatekeeper kinases
WO2016040951A1 (en) Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase
US7803829B2 (en) Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2015049371A1 (en) Methods for predicting the responsiveness of a patient affected with chronic myeloid leukemia (cml) to a treatment with a tyrosine kinase inhibitor (tki)
Barczyk et al. 4-Anilinoquinazoline Derivatives as the First Potent NOD1-RIPK2 Signaling Pathway Inhibitors at the Nanomolar Range
Chahal et al. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
CN102027371A (zh) Parp相互作用分子的鉴定方法和parp蛋白的纯化方法
EP2628482A1 (de) Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
HK1129039A (en) Use of a kinase inhibitor for the treatment of particular resistant tumors
Lin et al. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1129039

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1129039

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120815

Termination date: 20160329

CF01 Termination of patent right due to non-payment of annual fee